Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prion-like transmission and propagation of human β-amyloid to the bank vole rodent model.

Acta neuropathologica·2026

Same author

Gender and Diversity Trends Among Hand Fellowship Training Programs in the United States.

Plastic and reconstructive surgery. Global open·2026

Same author

A Multidisciplinary Analytical Strategy for the Authentication and Quality Assessment of Bromelain in Dietary Supplements.

International journal of molecular sciences·2026

Same author

Multi-target approaches to prion disease drug discovery: a status update.

Expert opinion on drug discovery·2026

Same author

Sodium valproate induces pancreatic injury by disruption of one-carbon metabolism.

British journal of pharmacology·2026

Same author

Continuous and reversible electrical-tuning of fluorescent decay rate via Fano resonance.

Nanotechnology·2026

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

Modulation of alpha-synuclein aggregation by dopamine analogs.

Diane Latawiec¹, Fernando Herrera, Alpan Bek

¹Department of Neurobiology, Scuola Internazionale Superiore di Studi Avanzati-International School for Advanced Studies, Trieste, Italy.

|February 20, 2010

Summary

Researchers explored how dopamine affects alpha-synuclein aggregation, a key factor in Parkinson's disease. They identified new compounds that can modulate this process, offering potential therapeutic strategies.

More Related Videos

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Technique for Intranasal Administration of α-Synuclein Aggregates

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 16, 2026

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Technique for Intranasal Administration of α-Synuclein Aggregates

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Area of Science:

Neuroscience
Biochemistry
Computational Biology

Background:

Alpha-synuclein (alpha-syn) protein aggregation is implicated in Parkinson's disease pathogenesis.
Dopamine and its derivatives may inhibit alpha-syn aggregation through non-covalent binding.

Purpose of the Study:

To identify novel ligands that can modulate alpha-syn fibrillization.
To investigate the potential of computational and experimental approaches for discovering such ligands.

Main Methods:

Screening of dopamine analogs from a library based on structural and electrostatic similarity.
Molecular dynamics simulations to assess ligand binding to alpha-syn.
In vitro fibrillization assays using atomic force microscopy (AFM) and transmission electron microscopy (TEM).

Main Results:

Five dopamine analogs were selected and tested in vitro.
Molecular dynamics confirmed non-covalent binding of analogs to alpha-syn, similar to dopamine.
All tested analogs affected alpha-syn aggregation, though to a lesser extent than dopamine.

Conclusions:

An integrated in silico/in vitro approach is effective for identifying ligands that interfere with unstructured protein fibrillization.
The identified dopamine analogs show potential for modulating alpha-syn aggregation, relevant to Parkinson's disease research.